Candriam S.C.A. Purchases 23,570 Shares of Insulet Corporation $PODD

Candriam S.C.A. increased its holdings in Insulet Corporation (NASDAQ:PODD) by 44.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,762 shares of the medical instruments supplier’s stock after acquiring an additional 23,570 shares during the period. Candriam S.C.A. owned about 0.11% of Insulet worth $24,118,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. American Century Companies Inc. boosted its position in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Nuveen LLC purchased a new position in shares of Insulet in the 1st quarter worth about $74,163,000. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of Insulet by 1,316.5% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after buying an additional 179,850 shares during the last quarter. Vanguard Group Inc. grew its position in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after buying an additional 178,976 shares during the period. Finally, AustralianSuper Pty Ltd increased its holdings in Insulet by 487.5% during the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after buying an additional 170,247 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PODD. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Oppenheimer upped their price objective on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Piper Sandler increased their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Rothschild & Co Redburn boosted their target price on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Finally, Wells Fargo & Company upped their price target on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by insiders.

Insulet Price Performance

Shares of NASDAQ PODD opened at $332.67 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The stock has a market cap of $23.40 billion, a PE ratio of 101.12, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The stock has a fifty day moving average of $323.89 and a 200-day moving average of $311.52.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same quarter last year, the company earned $1.08 EPS. The firm’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.